# The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine

> **NCT05279248** · PHASE4 · UNKNOWN · sponsor: **Zhejiang Provincial Center for Disease Control and Prevention** · enrollment: 300 (estimated)

## Conditions studied

- Human Papilloma Virus Infection Type 16
- Human Papilloma Virus Infection Type 18
- Measles
- Rubella
- Mumps

## Interventions

- **BIOLOGICAL:** HPV+MMR（0d），HPV（6m）
- **BIOLOGICAL:** HPV（0d），HPV（6m），MMR（7m）
- **BIOLOGICAL:** MMR（0d），HPV（1m），HPV（7m）

## Key facts

- **NCT ID:** NCT05279248
- **Lead sponsor:** Zhejiang Provincial Center for Disease Control and Prevention
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-25
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-20
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279248, "The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05279248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*